Immunome acquires AL102 a and AL101 from Ayala for $50M at closing

Immunome announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, to acquire AL102 and related drug candidate AL101 from Ayala. Based on the terms of the agreement, Immunome will pay Ayala $20M in cash and $30M in Immunome common stock at the closing and will pay up to an additional $37.5M in development and commercial milestone payments. Completion of the transaction is subject to customary conditions including Ayala obtaining the requisite stockholder approval. AL102 is an investigational small molecule gamma secretase inhibitor currently being evaluated in the randomized Phase 3 RINGSIDE international trial for the treatment of desmoid tumors – a debilitating soft tissue malignancy. AL102 is a potential once-daily oral treatment for desmoid tumors. Data from clinical trials have shown AL102 may be more effective in treating desmoid tumors than OGSIVEO or nirogacestat , which recently became the first treatment approved for desmoid tumors by the U.S. Food and Drug Administration in November 2023.